{"filing":{"accession_number":"0001654954-26-007986","cik":"0000901832","ticker":"AZN","company_name":"ASTRAZENECA PLC","form":"6-K","filing_date":"2026-09-01","report_date":"2026-09-01","primary_document":"a7349s.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/901832/000165495426007986/a7349s.htm"},"events":[{"id":30777,"run_id":28215,"accession_number":"0001654954-26-007986","anchor_item_number":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"AstraZeneca announced the completion of an exclusive license agreement with Dizal Pharmaceutical to acquire worldwide rights to develop and commercialize Zegfrovy (sunvozertinib), an oral EGFR inhibitor for lung cancer. The transaction involves an upfront payment of $600 million plus up to $900 million in milestone payments, representing a material acquisition of intellectual property and commercial rights that would affect investor assessment of the company's oncology portfolio and capital deployment.","company_name":"ASTRAZENECA PLC","ticker":"AZN","filing_date":"2026-09-01","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":33485,"accession_number":"0001654954-26-007986","item_number":null,"item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"AstraZeneca announced the completion of an exclusive license agreement with Dizal Pharmaceutical to acquire worldwide rights to develop and commercialize Zegfrovy (sunvozertinib), an oral EGFR inhibitor for lung cancer. The transaction involves an upfront payment of $600 million plus up to $900 million in milestone payments, representing a material acquisition of intellectual property and commercial rights that would affect investor assessment of the company's oncology portfolio and capital deployment.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-01T11:12:11.531575+00:00","company_name":"ASTRAZENECA PLC","ticker":"AZN","filing_date":"2026-09-01"}]}